MAS related GPR family member DGenealiases: MRGD · TGR7
Q-omics provides the consensus-scored MRGPRD profile across patient tissues and cancer cell-line models. MRGPRD expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MRGPRD is differentially expressed in 7, with the highest sampling consensus in BLCA. Additionally, MRGPRD RNA expression shows 10,003 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, BLCA, and TGCT as cancer lineages where MRGPRD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRGPRD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRGPRD survival associations across molecular data types. MRGPRD RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRGPRD RNA expression–survival associations across cancer types. High MRGPRD expression shows unfavorable associations in KICH, CHOL and KIRC, but favorable associations in UCS, UCEC and SARC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for MRGPRD RNA expression.
This table summarizes MRGPRD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MRGPRD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRGPRD shows lower tumor expression in BLCA, STAD, COAD, READ, UCEC and PRAD. The BLCA box plot shows higher MRGPRD RNA expression in normal versus tumor tissue (log2 FC = −0.362, t-test p = .005).
This table shows molecular features associated with MRGPRD in patient tissues and cancer cell lines. In patient samples, MRGPRD shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MRGPRD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
